Characterization of human class-switched polymeric (immunoglobulin M [IgM] and IgA) anti-human immunodeficiency virus type 1 antibodies 2F5 and 2G12.
We have previously generated human monoclonal anti-human immunodeficiency virus type 1 (anti-HIV-1) antibodies 2F5IgG and 2G12IgG with an exceptional cross-clade neutralizing potential. 2F5IgG and 2G12IgG passively administrated to macaques were able to confer complete protection from both intravenous and mucosal challenge with pathogenic HIV-simian immunodeficiency virus chimeric strains and have shown beneficial effects in a phase-1 clinical trial. We now class-switched 2F5 and 2G12 to the immunoglobulin M (IgM) or IgA isotype, to enforce features like avidity, complement activation, or the potential to neutralize mucosal transmission. For this purpose we expressed functional polymeric 2F5 and 2G12 antibodies in CHO cells and evaluated their anti-HIV-1 activity in vitro. The class switch had a strong impact on the protective potential of 2F5 and 2G12. 2G12IgM inhibited HIV-1 infection of peripheral blood mononuclear cell cultures up to 28-fold-more efficiently than the corresponding IgG and neutralized all of the primary isolates tested. The 2F5 and 2G12 antibodies of all isotypes were able to interact with active human serum to inhibit viral infection. Furthermore, we demonstrated that polymeric 2F5 and 2G12 antibodies but not the corresponding IgGs could interfere with HIV-1 entry across a mucosal epithelial layer in vitro. Although polymeric 2F5 antibodies had only limited potential in the standard neutralization assay, the results from the mucosal assay suggest that 2F5 and 2G12 antibodies may have a high potential to prevent natural HIV-1 transmission in vivo.
Wolbank
Susanne
S
Institute of Applied Microbiology, University of Agriculture, A-1190 Vienna, Austria.
Kunert
Renate
R
Stiegler
Gabriela
G
Katinger
Hermann
H
D000818:Animals; D000911:Antibodies, Monoclonal / Q000235:genetics / Q000276:immunology; D000918:Antibody Specificity; D016466:CHO Cells; D002460:Cell Line; D006224:Cricetinae; D003588:Cytopathogenic Effect, Viral / Q000276:immunology; D015483:HIV Antibodies / Q000235:genetics* / Q000276:immunology*; D015497:HIV-1 / Q000276:immunology* / Q000472:pathogenicity; D006801:Humans; D007070:Immunoglobulin A / Q000235:genetics* / Q000276:immunology*; D017578:Immunoglobulin Class Switching; D007075:Immunoglobulin M / Q000235:genetics* / Q000276:immunology*; D009500:Neutralization Tests; D011994:Recombinant Proteins / Q000235:genetics / Q000276:immunology; D015302:Simian Immunodeficiency Virus / Q000276:immunology / Q000472:pathogenicity
D000911:Antibodies, Monoclonal; D015483:HIV Antibodies; D007070:Immunoglobulin A; D007075:Immunoglobulin M; D011994:Recombinant Proteins; C034639:polymeric IgA; C024242:polymeric IgM